2024 연구성과 (9 / 286)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| WoS | SCOPUS | Document Type | Document Title | Abstract | Authors | Affiliation | ResearcherID (WoS) | AuthorsID (SCOPUS) | Author Email(s) | Journal Name | JCR Abbreviation | ISSN | eISSN | Volume | Issue | WoS Edition | WoS Category | JCR Year | IF | JCR (%) | FWCI | FWCI Update Date | WoS Citation | SCOPUS Citation | Keywords (WoS) | KeywordsPlus (WoS) | Keywords (SCOPUS) | KeywordsPlus (SCOPUS) | Language | Publication Stage | Publication Year | Publication Date | DOI | JCR Link | DOI Link | WOS Link | SCOPUS Link |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ○ | Meeting Abstract | Beneficial effect of combined radiation therapy in atezolizumab plus bevacizumab treatment of hepatocellular carcinoma patients with main portal vein tumor thrombosis | Hwang, Sangyoun; Woo, Hyun Young; Heo, Jeong; Kim, Hyung Jun; Park, Young Joo; Yi, Kiyoun; Lee, Yu Rim; Park, Soo Young; Chung, Woo Jin; Jang, Byoung Kuk; Tak, Won Young | Dongnam Inst Radiol & Med Sci, Dept Internal Med, Busan, South Korea; Pusan Natl Univ, Pusan Natl Univ Hosp, Dept Internal Med, Coll Med, Busan, South Korea; Pusan Natl Univ Hosp, Biomed Res Inst, Busan, South Korea; Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Internal Med, Daegu, South Korea; Keimyung Univ, Dept Internal Med, Sch Med, Daegu, South Korea | Heo, Jeong/MHQ-1390-2025 | jheo@pusan.ac.kr; | JOURNAL OF HEPATOLOGY | J HEPATOL | 0168-8278 | 1600-0641 | 80 | SCIE | GASTROENTEROLOGY & HEPATOLOGY | 2024 | 33 | 1.7 | 0 | English | 2024 | 2024-06 | 바로가기 | 바로가기 | |||||||||||||||
| ○ | Meeting Abstract | CheckpointPx: A predictive radiology AI model of immune checkpoint inhibitor (ICI) benefit in non-small cell lung cancer (NSCLC) | Lee, Seyoung; Hiremath, Amogh; Lee, Jeeyeon; Kim, Haseok; Zhang, Kai; Lee, Salie; Yadav, Monica; Chung, Liam Il Young; Kim, Hye Sung; Djunadi, Trie Arni; Kim, Yuchan; Hong, Ilene; Kang, Grace; Cho, Amy; Velichko, Yury; Gupta, Amit; Velcheti, Vamsidhar; Madabhushi, Anant; Braman, Nathaniel; Chae, Young Kwang | Kyungpook Natl Univ, Sch Med, Daegu, South Korea; Picture Hlth, Cleveland, OH USA; Kyungpook Natl Univ Hosp, Daegu, South Korea; Univ Texas Austin, Weatherford, TX USA; Picture Hlth Inc, Cleveland, OH USA; Feinberg Sch Med, Chicago, IL USA; Northwestern Univ, Feinberg Sch Med, Chicago, IL USA; Richmond Univ, Med Ctr, Staten Isl, NY USA; Northwestern Univ, Chicago, IL USA; Univ Hosp Cleveland Med Ctr, Cleveland, OH USA; NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY USA | Madabhushi, Anant/AAG-2908-2019; Kim, Hye Sung/LQV-0440-2024; Kim, Haseok/MDT-5309-2025; Chung, Liam Il-Young/IQU-0821-2023; Hiremath, Amogh/AAO-3178-2021 | JOURNAL OF CLINICAL ONCOLOGY | J CLIN ONCOL | 0732-183X | 1527-7755 | 42 | 16 | SCIE | ONCOLOGY | 2024 | 41.9 | 1.7 | 0 | English | 2024 | 2024-06-01 | 바로가기 | 바로가기 | |||||||||||||||
| ○ | Meeting Abstract | Early versus conventional adjuvant chemotherapy in stage III colon cancer: A multicenter, randomized, open-label, phase 3 trial | Park, Soo Yeun; Kim, So Hyun; Lee, Kyung Ha; Song, Seung Ho; Kim, Hye Jin; Kim, Jong Gwang; Kang, Byung Woog; Baek, Seong Kyu; Jeong, Woon Kyung; Bae, Sung Uk; Lee, In Kyu; Lee, Yoon Suk; Son, Gyung Mo; Bae, Ki Beom; Kim, Ji Yeon; Park, Jun Seok; Choi, Gyu-Seog | Kyungpook Natl Univ, Colorectal Canc Ctr, Chilgok Hosp, Daegu, South Korea; Yeungnam Univ, Div Colon & Rectum, Dept Surg, Coll Med, Daegu, South Korea; Chungnam Natl Univ, Chungnam Natl Univ Hosp, Dept Surg, Coll Med, Dajeon, South Korea; Kyungpook Natl Univ, Daegu, South Korea; Kyungpook Natl Univ, Med Ctr, Sch Med, Colorectal Canc Ctr, Daegu, South Korea; Kyungpook Natl Univ, Sch Med, Dept Oncol Hematol, Med Ctr, Daegu, South Korea; Kyungpook Natl Univ, Sch Med, Dept Oncol Haematol, Med Ctr, Daegu, South Korea; Keimyung Univ, Sch Med, Dept Surg, Dongsan Med Ctr, Daegu, South Korea; Catholic Univ Korea, Seoul St Marys Hosp, Dept Surg, Coll Med, Seoul, South Korea; Pusan Natl Univ, Sch Med, Dept Surg, Yangsan Hosp, Busan, South Korea; Inje Univ, Busan Paik Hosp, Paik Inst Clin Res, Coll Med,Dept Surg, Busan, South Korea; Chungnam Natl Univ, Chungnam Natl Univ Hosp, Dept Surg, Coll Med, Daejeon, South Korea | Kim, Jong/G-7779-2012; Son, Gyung/W-2979-2019; Park, Junsu/IQU-2241-2023; Kim, Sung-Bae/JXL-8219-2024; Bae, Sung/W-1915-2019; Kim, Hye/W-1059-2019 | JOURNAL OF CLINICAL ONCOLOGY | J CLIN ONCOL | 0732-183X | 1527-7755 | 42 | 16 | SCIE | ONCOLOGY | 2024 | 41.9 | 1.7 | 0 | English | 2024 | 2024-06-01 | 바로가기 | 바로가기 | |||||||||||||||
| ○ | Meeting Abstract | EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. | Lencioni, Riccardo; Kudo, Masatoshi; Erinjeri, Joseph; Qin, Shukui; Ren, Zhenggang; Chan, Stephen; Arai, Yasuaki; Heo, Jeong; Mai, Ahn; Escobar, Jose; Lopez Chuken, Yamil Alonso; Yoon, Jung-Hwan; Tak, Won Young; Suttichaimongkol, Tanita; Bouattour, Mohamed; Lin, Shi-Ming; Zotkiewicz, Magdalena; Udoye, Stephanie; Cohen, Gordon; Sangro, Bruno | Univ Pisa, Sch Med, Dept Diagnost & Intervent Radiol, Pisa, Italy; Kindai Univ, Fac Med, Dept Gastroenterol & Hepatol, Osaka, Japan; Mem Sloan Kettering Canc Ctr, Intervent Radiol Serv, New York, NY USA; Nanjing Univ Chinese Med, Jinling Hosp, Canc Ctr, Nanjing, Peoples R China; Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China; Chinese Univ Hong Kong, Sir Yue Kong Pao Ctr Canc, State Key Lab Translat Oncol, Dept Clin Oncol, Hong Kong, Peoples R China; Natl Canc Ctr, Dept Diagnost Radiol, Chuo Ku, Tokyo, Japan; Pusan Natl Univ, Coll Med, Dept Internal Med, Pusan, South Korea; Pusan Natl Univ Hosp, Biomed Res Inst, Pusan, South Korea; Nhan Dan Gia Dinh Hosp, Gen Surg Dept, Ho Chi Minh City, Vietnam; Hosp San Lucas Cardiol Sureste, Chiapas, Mexico; I Can Oncol Ctr, New Leon, Mexico; Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul, South Korea; Seoul Natl Univ, Liver Res Inst, Coll Med, Seoul, South Korea; Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea; Khon Kaen Univ, Fac Med, Dept Med, Div Gastroenterol & Hepatol, Khon Kaen, Thailand; Hop Beaujon, AP HP, Med Oncol, Paris, France; Chang Gung Mem Hosp, Linkou Med Ctr, Dept Internal Med, Taoyuan, Taiwan; AstraZeneca, Oncol Biometr, Late Oncol Stat, Warsaw, Poland; AstraZeneca, Global Med Dev, Gaithersburg, MD USA; Clin Univ Navarra, Liver Unit, Pamplona, Spain; Clin Univ Navarra, HPB Oncol Area, Pamplona, Spain; CIBEREHD, Pamplona, Spain | Sangro, Bruno/AFW-4106-2022; Heo, Jeong/MHQ-1390-2025; Lin, Shiming/NPI-5122-2025; Kudo, Masatoshi/AAA-9744-2019; Suttichaimongkol, Tanita/JDW-6886-2023 | JOURNAL OF CLINICAL ONCOLOGY | J CLIN ONCOL | 0732-183X | 1527-7755 | 42 | 3_SUPPL | SCIE | ONCOLOGY | 2024 | 41.9 | 1.7 | 114 | 261-2388-2665-6735; 283-424-425; 613-225-313; 613-225-3248-9559-9794; 3282-3306-7927-3999; 281-318-430; 281-9641-2654-9244-11272; 12; 7; 4; 4; 3; 3; 2; 2018; 182; 2018; 182; 7; 4; 3; 3; 38092-17498; 38092-26368; 11; 1 | English | 2024 | 2024-01-20 | 10.1200/jco.2024.42.3_suppl.lba432 | 바로가기 | 바로가기 | 바로가기 | ||||||||||||
| ○ | Meeting Abstract | Enhanced dacarbazine efficacy in advanced melanoma patients previously treated with immune checkpoint inhibitors in Korea | Lee, Soo Jung; Na, Jihyun; Lee, In Hee; Lee, Jeeyeon; Lee, Seok-Jong | Kyungpook Natl Univ, Kyungpook Natl Univ Chilgok Hosp, Daegu, South Korea; Univ Ulsan, Ulsan Univ Hosp, Dept Hematol & Oncol, Coll Med, Ulsan, South Korea; Kyungpook Natl Univ Hosp, Daegu, South Korea; Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Daegu, South Korea | Lee, Joong/A-5417-2013 | JOURNAL OF CLINICAL ONCOLOGY | J CLIN ONCOL | 0732-183X | 1527-7755 | 42 | 16 | SCIE | ONCOLOGY | 2024 | 41.9 | 1.7 | 0 | English | 2024 | 2024-06-01 | 바로가기 | 바로가기 | |||||||||||||||
| ○ | Meeting Abstract | Evaluation of malignant potential based on infection with high-risk human papillomaviruses 16, 52, and 58 in the uterine cervix | Lee, Seung-Mi; Lee, Hyun-Jung; Lee, Juhun | Kyungpook Natl Univ Hosp, Dept Obstet & Gynecol, Daegu, South Korea | JOURNAL OF CLINICAL ONCOLOGY | J CLIN ONCOL | 0732-183X | 1527-7755 | 42 | 16 | SCIE | ONCOLOGY | 2024 | 41.9 | 1.7 | 0 | English | 2024 | 2024-06-01 | 바로가기 | 바로가기 | ||||||||||||||||
| ○ | Meeting Abstract | Factors influencing HBsAg clearance in children with chronic hepatitis B undergoing antiviral therapy: significance of age at treatment onset and HBeAg titer dynamics | Choe, Byung-Ho; Hong, Sukjin | Kyungpook Natl Univ, Childrens Hosp, Daegu, South Korea; Daegu Catholic Univ, Med Ctr, Daegu, South Korea | Choe, Byung-Ho/KSM-6251-2024 | bhchoi@knu.ac.kr; | JOURNAL OF HEPATOLOGY | J HEPATOL | 0168-8278 | 1600-0641 | 80 | SCIE | GASTROENTEROLOGY & HEPATOLOGY | 2024 | 33 | 1.7 | 0 | English | 2024 | 2024-06 | 바로가기 | 바로가기 | |||||||||||||||
| ○ | Meeting Abstract | Harmonization radiomics model to predict immune checkpoint inhibitor-related pneumonitis (CIP) in patients with non-small cell lung cancer (NSCLC) | Yadav, Monica; Lee, Jeeyeon; Kim, Haseok; Lee, Seyoung; Um, Taegyu; Lee, Salie; Djunadi, Trie Arni; Chung, Liam Il Young; Yu, Jisang; Rodrigues, Darren; Gennaro, Nicolo; Kim, Leeseul; Kim, Yuchan; Nam, Myungwoo; Hong, Ilene; Jang, Jessica; Cho, Amy; Kang, Grace; Velichko, Yury; Chae, Young Kwang | Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; Kyungpook Natl Univ Hosp, Daegu, South Korea; Univ Texas Austin, Weatherford, TX USA; Kyungpook Natl Univ, Sch Med, Daegu, South Korea; Feinberg Sch Med, Chicago, IL USA; Richmond Univ, Med Ctr, Staten Isl, NY USA; Dign Hlth, St Rose Dominican Hosp, Henderson, NV USA; Northwestern Univ, Chicago, IL 60611 USA; Ascens St Francis Hosp, Evanston, IL USA; Lincoln Med & Mental Hlth Ctr, Bronx, NY 10451 USA; Northwestern Med Devleopmental Therapeut Inst, Chicago, IL USA; Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Dev Therapeut, Chicago, IL 60611 USA | Kim, Haseok/MDT-5309-2025; Gennaro, Nicolò/P-1776-2019; Chung, Liam Il-Young/IQU-0821-2023 | JOURNAL OF CLINICAL ONCOLOGY | J CLIN ONCOL | 0732-183X | 1527-7755 | 42 | 16 | SCIE | ONCOLOGY | 2024 | 41.9 | 1.7 | 0 | English | 2024 | 2024-06-01 | 바로가기 | 바로가기 | |||||||||||||||
| ○ | Meeting Abstract | Long-term oncologic outcome of breast-conserving surgery in breast cancer with BRCA 1/2 mutation (ON-BRCA II, KoREa-BSG 06) | Lee, Janghee; Ryu, Jai Min; Kim, Hong-Kyu; Park, Hyung Seok; Kang, Byeongju; Ahn, Sung Gwe; Chung, Min Sung; Shin, Seon-Hi; Go, Junwon; Kim, Sanghwa; Kim, Eun Young; Kang, Young-Joon; Min, Sun Young; Lee, Moo Hyun; Shin, Eunju; Shin, Jisoo; Lee, Sae Byul; Cha, Chihwan | Hallym Univ, Dongtan Sacred Heart Hosp, Dept Surg, Dongtan, South Korea; Sungkyunkwan Univ, Div Breast Surg, Dept Surg, Samsung Med Ctr,Sch Med, Seoul, South Korea; Seoul Natl Univ, Seoul Natl Univ Hosp, Dept Surg, Coll Med, Seoul, South Korea; Yonsei Univ, Div Breast Surg, Dept Surg, Coll Med, Seoul, South Korea; Kyungpook Natl Univ Hosp, Daegu, South Korea; Yonsei Univ, Gangnam Severance Hosp, Dept Surg, Coll Med, Seoul, South Korea; Hanyang Univ, Seoul, South Korea; Hanyang Univ, Med Res Collaborating Ctr, Biostat Consulting & Res Lab, Seoul, South Korea; Hallym Univ, Sacred Heart Hosp, Dept Surg, Anyang, South Korea; Sungkyunkwan Univ, Kangbuk Samsung Hosp, Dept Gen Surg, Sch Med, Seoul, South Korea; Catholic Univ Korea, Incheon St Marys Hosp, Dept Surg, Coll Med, Incheon, South Korea; Kyung Hee Univ, Sch Med, Seoul, South Korea; Keimyung Univ, Dept Surg, Sch Med, Daegu, South Korea; Univ Ulsan, Div Breast Surg, Dept Surg, Asan Med Ctr,Coll Med, Seoul, South Korea; Sungkyunkwan Univ, Div Breast Surg, Samsung Med Ctr, Dept Surg,Sch Med, Seoul, South Korea; Asan Med Ctr, Seoul, South Korea; Hanyang Univ, Seoul Hosp, Dept Surg, Coll Med, Seoul, South Korea | Kim, Seunghyun/AAA-3402-2022; Kim, Seonghwan/AAZ-1679-2021; Cha, Chihwan/AAS-4502-2021; Park, Hong-Gyu/C-6000-2008; Ahn, Sung Gwe/AFD-8122-2022; Kim, Joong-goo/AEW-1096-2022; Kim, Chang Gon/IAP-6721-2023 | JOURNAL OF CLINICAL ONCOLOGY | J CLIN ONCOL | 0732-183X | 1527-7755 | 42 | 16 | SCIE | ONCOLOGY | 2024 | 41.9 | 1.7 | 0 | English | 2024 | 2024-06-01 | 바로가기 | 바로가기 | |||||||||||||||
| ○ | Meeting Abstract | Magnetic resonance texture analysis for predicting histologic tumor type in endometrial cancer | Lee, Seung-Mi; Lee, Hyun-Jung; Lee, Juhun | Kyungpook Natl Univ Hosp, Dept Obstet & Gynecol, Daegu, South Korea | JOURNAL OF CLINICAL ONCOLOGY | J CLIN ONCOL | 0732-183X | 1527-7755 | 42 | 16 | SCIE | ONCOLOGY | 2024 | 41.9 | 1.7 | 0 | English | 2024 | 2024-06-01 | 바로가기 | 바로가기 | ||||||||||||||||
| ○ | Meeting Abstract | mRECIST outcomes in EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with/without bevacizumab in participants with embolization-eligible hepatocellular carcinoma | Sangro, Bruno; Kudo, Masatoshi; Erinjeri, Joseph; Qin, Shukui; Ren, Zhenggang; Chan, Stephen; Arai, Yasuaki; Heo, Jeong; Mai, Ahn; Escobar, Jose; Chuken, Yamil Alonso Lopez; Yoon, Jung-Hwan; Tak, Won Young; Suttichaimongkol, Tanita; Bouattour, Mohamed; Lin, Shi-Ming; Zotkiewicz, Magdalena; Ali, Sajid; Cohen, Gordon; Lencioni, Riccardo | Univ Navarra Clin, Liver Unit, Pamplona, Spain; Univ Navarra Clin, HPB Oncol Area, Pamplona, Spain; CIBEREHD, Pamplona, Spain; Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Osaka, Japan; Mem Sloan Kettering Canc Ctr, Intervent Radiol Serv, New York, NY USA; Jinling Hosp, Canc Ctr Nanjing, Nanjing, Peoples R China; Fudan Univ, Zhongshan Hosp, Liver Canc Inst, Dept Hepat Oncol, Shanghai, Peoples R China; Chinese Univ Hong Kong, State Key Lab Translat Oncol, Dept Clin Oncol, Sir Yue Kong Pao Ctr Canc, Hong Kong, Peoples R China; Natl Canc Ctr, Dept Diagnost Radiol, Chuo Ku, Tokyo, Japan; Pusan Natl Univ, Dept Internal Med, Coll Med, Pusan, South Korea; Pusan Natl Univ Hosp, Biomed Res Inst, Pusan, South Korea; Nhan Dan Gia Dinh Hosp, Dept Gen Surg, Ho Chi Minh City, Vietnam; Hosp San Lucas Cardiolog Sureste, Chiapas, Mexico; I Can Oncol Ctr, New Leon, Mexico; Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul, South Korea; Seoul Natl Univ, Coll Med, Liver Res Inst, Seoul, South Korea; Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea; Khon Kaen Univ, Dept Med, Div Gastroenterol & Hepatol, Fac Med, Khon Kaen, Thailand; Hop Beaujon, AP HP, Med Oncol, Paris, France; Chang Gung Mem Hosp, Linkou Med Ctr, Dept Internal Med, Taoyuan, Taiwan; AstraZeneca, Oncol Biometr, Late Oncol Stat, Warsaw, Poland; AstraZeneca, Late Dev Oncol, Cambridge, England; AstraZeneca, Global Med Dev, Gaithersburg, MD USA; Univ Pisa, Dept Diagnost & Intervent Radiol, Sch Med, Pisa, Italy | Lee, Jeong-Hoon/Q-1055-2018; Suttichaimongkol, Tanita/JDW-6886-2023; Heo, Jeong/MHQ-1390-2025; Kudo, Masatoshi/AAA-9744-2019; Sangro, Bruno/AFW-4106-2022; Lin, Shiming/NPI-5122-2025 | bsangro@unav.es; | JOURNAL OF HEPATOLOGY | J HEPATOL | 0168-8278 | 1600-0641 | 80 | SCIE | GASTROENTEROLOGY & HEPATOLOGY | 2024 | 33 | 1.7 | 1 | English | 2024 | 2024-06 | 바로가기 | 바로가기 | |||||||||||||||
| ○ | Meeting Abstract | Multinational randomized trial to investigate the efficacy of tenofovir alafenamide in reducing adverse clinical events in chronic hepatitis B patients who are beyond treatment indications by current guidelines (ATTENTION trial): first interim analysis | Lim, Young-Suk; Choi, Jonggi; Choi, Won-Mook; Kang, Wonseok; Kim, Gi-Ae; Kim, Hyung Joon; Lee, Jeong-Hoon; Lee, Yun Bin; Park, Neung Hwa; Kwon, So Young; Jang, Eun Sun; Park, Soo Young; Kim, Ji Hoon; Yu, Ming-Lung; Chen, Chien-Hung; Hsu, Yao-Chun (Holden); Bair, Ming-Jong; Cheng, Pin-Nan; Tung, Hung-Da; Chang, Te-Sheng; Chen, Chi-Yi; Lo, Chingchu; Tseng, Kuo-Chih; Yang, Sheng-Shun; Peng, Cheng-Yuan | Asan Med Ctr, Seoul, South Korea; Samsung Med Ctr, Seoul, South Korea; Kyung Hee Univ Hosp, Seoul, South Korea; Chung Ang Univ Hosp, Seoul, South Korea; Seoul Natl Univ Hosp, Seoul, South Korea; Ulsan Univ Hosp, Ulsan, South Korea; Konkuk Univ, Med Ctr, Seoul, South Korea; Seoul Natl Univ, Bundang Hosp, Seongnam, South Korea; Kyungpook Natl Univ Hosp, Daegu, South Korea; Korea Univ, Guro Hosp, Seoul, South Korea; Natl Sun Yat Sen Univ, Kaohsiung, Taiwan; Kaohsiung Chang Gung Mem Hosp, Kaohsiung, Taiwan; Fu Jen Catholic Univ, Kaohsiung, Taiwan; Mackay Mem Hosp, Taichung, Taiwan; Natl Cheng Kung Univ Hosp, Tainan, Taiwan; Chi Mei Hosp, Tainan, Taiwan; Chiayi Chang Gung Mem Hosp, Puzy City, Taiwan; Chia Yi Christian Hosp, Cia Yi, Taiwan; St Martin Hosp, Chiayi, Taiwan; Dalin Tzu Chi Hosp, Chiayi, Taiwan; Taichung Vet Gen Hosp, Taichung, Taiwan; China Med Univ Hosp, Taichung, Taiwan | Chen, ChiYi/KVZ-1550-2024; Kim, Gi-Ae/AAZ-2547-2021; Yu, Ming-Lung/C-9540-2009; CHEN, PEIJUN/ISB-4464-2023; Choi, Won-Mook/ABE-2662-2021; Choi, Jonggi/L-1521-2019; Lim, Young-Suk/AFQ-5165-2022; Peng, Chengyuan/LDR-1674-2024 | limys@amc.seoul.kr; | JOURNAL OF HEPATOLOGY | J HEPATOL | 0168-8278 | 1600-0641 | 80 | SCIE | GASTROENTEROLOGY & HEPATOLOGY | 2024 | 33 | 1.7 | 2 | English | 2024 | 2024-06 | 바로가기 | 바로가기 | |||||||||||||||
| ○ | ○ | Article | Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY | Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.The phase III PRODIGY study demonstrated that neoadjuvant chemotherapy with docetaxel, oxaliplatin, and S-1 (DOS) followed by surgery and adjuvant S-1 chemotherapy (CSC) improved progression-free survival (PFS) compared with surgery followed by adjuvant S-1 (SC) for patients with resectable locally advanced gastric cancer (LAGC) with clinical T2-3N+ or T4Nany disease. The primary end point was PFS. Overall survival (OS) was the secondary end point. We herein report the long-term follow-up outcomes, including OS, from this trial. A total of 238 and 246 patients were randomly assigned to the CSC and SC arms, respectively, and were treated (full analysis set). As of the data cutoff (September 2022), the median follow-up duration of the surviving patients was 99.5 months. Compared with SC, CSC significantly increased the OS (adjusted hazard ratio [HR], 0.72; stratified log-rank P = .027) with an 8-year OS rate of 63.0% and 55.1% for the CSC and SC arms, respectively. CSC also significantly improved the PFS (HR, 0.70; stratified log-rank P = .016). In conclusion, neoadjuvant DOS chemotherapy, as part of perioperative chemotherapy, prolonged the OS of Asian patients with LAGC relative to patients treated with surgery and adjuvant S-1. It should be considered one of the standard treatment options for patients with LAGC in Asia. | Kang, Yoon-Koo; Kim, Hyung-Don; Yook, Jeong Hwan; Park, Young-Kyu; Lee, Jong Seok; Kim, Young-Woo; Kim, Jin Young; Ryu, Min-Hee; Rha, Sun Young; Chung, Ik Joo; Kim, In-Ho; Oh, Sang Cheul; Park, Young Soo; Cheong, Jae-Ho; Jeong, Oh; Heo, Mi Hwa; Kim, Hark Kyun; Park, Chohyun; Yoo, Chang Hak; Kang, Seok Yun; Zang, Dae Young; Jang, You Jin; Sul, Ji Young; Kim, Jong Gwang; Kim, Beom Su; Beom, Seung-Hoon; Hwang, Jun-Eul; Ryu, Seung Wan; Kook, Myeong-Cherl; Ryoo, Baek-Yeol; Kim, Hyunki; Yoo, Moon-Won; Lee, Nam Su; Lee, Sang Ho; Noh, Sung Hoon | Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea; Univ Ulsan, Asan Med Ctr, Dept Surg, Seoul, South Korea; Chonnam Natl Univ, Dept Surg, Med Sch, Hwasun, South Korea; Univ Ulsan, Coll Med, Asan Med Ctr, Dept Radiol, Seoul, South Korea; Natl Canc Ctr, Ctr Gastr Canc Res Inst & Hosp, Grad Sch Canc Sci & Policy, Goyang, South Korea; Keimyung Univ Dongsan Hosp, Dept Internal Med, Div Hemato Oncol, Daegu, South Korea; Yonsei Univ, Coll Med, Yonsei Canc Ctr, Dept Internal Med, Seoul, South Korea; Chonnam Natl Univ, Chonnam Natl Univ Hwasun Hosp, Dept Internal Med, Med Sch, Jeonnam, South Korea; Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Internal Med,Div Med Oncol, Seoul, South Korea; Korea Univ Guro Hosp, Dept Internal Med, Seoul, South Korea; Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pathol, Seoul, South Korea; Yonsei Univ Hlth Syst, Yonsei Canc Ctr, Dept Surg, Seoul, South Korea; Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Surg, Seoul, South Korea; Sungkyunkwan Univ, Kangbuk Samsung Hosp, Dept Surg, Sch Med, Seoul, South Korea; Ajou Univ, Dept Hematol Oncol, Sch Med, Suwon, South Korea; Hallym Univ, Dept Internal Med, Sacred Heart Hosp, Anyang, South Korea; Korea Univ Guro Hosp, Dept Surg, Seoul, South Korea; Chungnam Natl Univ Hosp, Dept Surg, Daejeon, South Korea; Kyungpook Natl Univ, Dept Internal Med, Daegu, South Korea; Keimyung Univ, Dept Surg, Dongsan Med Ctr, Daegu, South Korea; Yonsei Univ, Dept Pathol, Coll Med, Seoul, South Korea; Soon Chun Hyang Univ Hosp, Dept Internal Med, Seoul, South Korea; Kosin Univ Gospel Hosp, Dept Surg, Busan, South Korea; Yonsei Univ Hlth Syst, Gangnam Severance Hosp, Dept Surg, Seoul, South Korea | Kim, Jin Il/JWP-3629-2024; Kim, Dong-Wan/J-5391-2012; Kim, Hee/F-4594-2014; Kang, Yoon-Koo/ABL-4264-2022; Kim, Beomsu/MBG-6090-2025; Kim, Sung-Bae/JXL-8219-2024 | 7402784198; 56526231200; 7006991559; 10140547300; 59699991100; 57215377843; 57196169650; 7101754860; 7006023235; 15735604200; 55477690000; 55647062500; 59135056800; 57226064576; 26428191900; 57217563491; 57205288596; 7408416020; 7201746340; 14620681300; 57216641597; 35573659700; 57208299487; 34771414000; 59652872000; 52563182100; 57216575473; 55420795900; 7003734725; 6603026326; 57965263900; 23020267900; 35083799500; 57202883789; 59307439800 | ykkang@amc.seoul.kr; | JOURNAL OF CLINICAL ONCOLOGY | J CLIN ONCOL | 0732-183X | 1527-7755 | 42 | 25 | SCIE | ONCOLOGY | 2024 | 41.9 | 1.7 | 5.58 | 2025-05-07 | 17 | 17 | GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA; OPEN-LABEL; PERIOPERATIVE CHEMOTHERAPY; DOUBLE-BLIND; CAPECITABINE; NIVOLUMAB | Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Docetaxel; Drug Combinations; Female; Gastrectomy; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Tegafur; docetaxel; gimeracil plus oteracil potassium plus tegafur; oxaliplatin; antineoplastic agent; docetaxel; oteracil; oxaliplatin; S 1 (combination); tegafur; adjuvant chemotherapy; adjuvant therapy; adult; advanced cancer; Article; cancer combination chemotherapy; cancer survival; clinical feature; controlled study; demographics; ECOG Performance Status; female; follow up; gastroesophageal junction; hazard ratio; human; intention to treat analysis; locally advanced gastric cancer; major clinical study; male; middle aged; neoadjuvant chemotherapy; overall survival; phase 3 clinical trial; primary tumor site; progression free survival; randomized controlled trial; stomach cancer; adjuvant chemotherapy; aged; clinical trial; drug combination; drug therapy; gastrectomy; mortality; multicenter study; neoadjuvant therapy; pathology; stomach tumor | English | 2024 | 2024-09-01 | 10.1200/jco.23.02167 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |||
| ○ | Meeting Abstract | Phase IB/II trial of durvalumab plus doxorubicin combination in patients with advanced soft-tissue sarcoma | Cho, Hee Jin; Sim, Nam Suk; Shin, Su-Jin; Yun, Kum-Hee; Lee, Young Han; Jun, Hyun Jung; Rha, Sun Young; Kim, Hyo Song | Kyungpook Natl Univ, Dept Biomed Convergence Sci & Technol, Daegu, South Korea; Yonsei Univ, Dept Otorhinolaryngol, Coll Med, Seoul, South Korea; Yonsei Univ, Dept Pathol, Coll Med, Seoul, South Korea; Yonsei Univ, Div Med Oncol, Dept Internal Med, Yonsei Canc Ctr,Coll Med, Seoul, South Korea; Yonsei Univ, Dept Radiol, Coll Med, Seoul, South Korea; Seoul Med Ctr, Div Hematol Oncol, Dept Med, Seoul, South Korea; Yonsei Univ, SongDang Inst Canc Res, Div Med Oncol, Dept Internal Med,Coll Med,Yonsei Canc Ctr, Seoul, South Korea | Park, Young-Jae/AAJ-8828-2020; Kim, Hyun/D-5568-2011 | JOURNAL OF CLINICAL ONCOLOGY | J CLIN ONCOL | 0732-183X | 1527-7755 | 42 | 16 | SCIE | ONCOLOGY | 2024 | 41.9 | 1.7 | 2 | English | 2024 | 2024-06-01 | 바로가기 | 바로가기 | |||||||||||||||
| ○ | ○ | Article | Phase Ib/IIa randomized study of heterologous ChAdOx1HBV/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB | Background & aims: The induction of effective CD8+ T cells is thought to play a critical role in the functional cure of chronic hepatitis B (CHB). Additionally, the use of checkpoint inhibitors is being evaluated to overcome T-cell dysfunction during CHB. Methods: A chimpanzee adenoviral vector (ChAdOx1-HBV) and a Modified vaccinia Ankara boost (MVA-HBV) encoding the inactivated polymerase, core, and S region from a consensus genotype C HBV were studied. Fifty-five patients with virally suppressed CHB and HBsAg 0.7 log(10) at 2 months after the last dose. Group 3 (n = 18) had mean reductions in HBsAg of 0.76 log(10) and 0.80 log(10) (p <0.001) at 2 and 7 months after the last dose. Two patients developed persistent non-detectable HBsAg levels. CD4+ and CD8+ antigen-specific T-cell responses were generated and there was a correlation between IFN-gamma ELISpot response and HBsAg decline in Group 2. Conclusions: VTP-300 induced CD4+ and CD8+ T cells and lowered HBsAg in a subset of patients with baseline values below 100 IU/ml. The addition of LDN resulted in significant reduction in surface antigen. VTP-300 is a promising immunotherapeutic that warrants further development alone or in combination therapies. | Tak, Won Young; Chuang, Wan-Lobg; Chen, Chi-Yi; Tseng, Kuo-Chih; Lim, Young-Suk; Lo, Gin-Ho; Heo, Jeong; Agarwal, Kaushik; Bussey, Louise; Teoh, Sui Lynn; Tria, A.; Brown, Anthony; Anderson, Katie; Vardeu, Antonella; O'Brien, Susanne; Kopycinski, Jakub; Kolenovska, Radka; Barnes, Ellie; Evans, Thomas | Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Daegu, South Korea; Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Kaohsiung, Taiwan; Chia Yi Christian Hosp, Chiayi, Taiwan; Dalin Tzu Chi Gen Hosp, Hualien, Taiwan; Univ Ulsan, Coll Med, Coll Med, Seoul, South Korea; E Da Hosp, Kaohsiung, Taiwan; Pusan Natl Univ, Pusan Natl Univ Hosp, Dept Internal Med, Coll Med, Busan, South Korea; Pusan Natl Univ Hosp, Biomed Res Inst, Busan, South Korea; Kings Coll Hosp NHS Fdn Trust, Inst Liver Studies, London, England; Vaccitech, Harwell, Oxon, South Korea; ICON Clin Res, Med Serv, Singapore, Singapore; Univ Oxford, Nuffield Dept Med, Oxford, England; Oxford Univ Hosp NHS Trust, NIHR Oxford Biomed Res Ctr, Oxford, England | Chuang, Wan-Long/C-9536-2009; Heo, Jeong/MHQ-1390-2025; Lim, Young-Suk/AFQ-5165-2022; Chen, ChiYi/KVZ-1550-2024 | 7004074582; 57154888300; 7501967827; 8588819700; 57226548822; 57209282095; 8422238800; 57209840598; 57226611954; 59355085100; 59355611700; 55219821200; 57194331025; 55621616700; 59355439200; 24070753200; 59196468100; 57551970100; 7401453852 | tom.evans@barinthusbio.com; | JOURNAL OF HEPATOLOGY | J HEPATOL | 0168-8278 | 1600-0641 | 81 | 6 | SCIE | GASTROENTEROLOGY & HEPATOLOGY | 2024 | 33 | 1.7 | 2.31 | 2025-05-07 | 11 | 10 | hepatitis; therapeutic vaccine; checkpoint inhibitors | SURFACE-ANTIGEN LEVELS; HEPATITIS-B PATIENTS; T-CELL RESPONSES; VECTORED VACCINES; HBV; SEROCLEARANCE; BLOCKADE; EFFICACY; HIV-1 | checkpoint inhibitors; hepatitis; therapeutic vaccine | Adult; Aged; CD8-Positive T-Lymphocytes; ChAdOx1 nCoV-19; Female; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immune Checkpoint Inhibitors; Male; Middle Aged; Nivolumab; Treatment Outcome; Vaccination; Vaccinia virus; alanine aminotransferase; besifovir; CD4 antigen; CD8 antigen; entecavir; hepatitis B surface antibody; hepatitis B surface antigen; interleukin 2; nivolumab; tenofovir alafenamide; tenofovir disoproxil; vaxzevria; hepatitis B surface antigen; hepatitis B vaccine; immune checkpoint inhibitor; nivolumab; vaxzevria; adult; arthralgia; Article; aspartate aminotransferase to platelet ratio index; CD8+ T lymphocyte; chronic hepatitis B; clinical article; consensus; controlled study; demographics; fatigue; female; headache; human; immune response; injection site pain; injection site reaction; low drug dose; malaise; male; middle aged; monotherapy; nausea; peripheral blood mononuclear cell; risk assessment; T lymphocyte; vaccination; vaccine immunogenicity; aged; CD8+ T lymphocyte; chronic hepatitis B; clinical trial; drug therapy; genetics; Hepatitis B virus; immunology; phase 1 clinical trial; phase 2 clinical trial; procedures; randomized controlled trial; treatment outcome; vaccination; Vaccinia virus; virology | English | 2024 | 2024-12 | 10.1016/j.jhep.2024.06.027 | 바로가기 | 바로가기 | 바로가기 | 바로가기 |
페이지 이동: